Back to top
more

Dynavax Technologies (DVAX)

(Delayed Data from NSDQ)

$10.33 USD

10.33
4,776,516

-0.73 (-6.60%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $10.33 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Dynavax Signs a Pact to Develop Universal Influenza Vaccine

by Zacks Equity Research

Dynavax (DVAX) inks a deal with Mount Sinai to develop a universal influenza vaccine candidate using its CpG 1018 adjuvant. The development is funded under a contract win from NIAID.

Zacks Equity Research

Dynavax Technologies (DVAX) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Dynavax Technologies (DVAX) closed at $8.51, marking a -1.73% move from the previous day.

Zacks Equity Research

Do Options Traders Know Something About Dynavax Technologies (DVAX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.

Ritujay Ghosh headshot

4 Solid Stocks to Buy on Renewed Hopes of Coronavirus Vaccine

by Ritujay Ghosh

The past few months have seen pharmaceutical companies making every effort to develop a vaccine for the novel coronavirus.

Zacks Equity Research

Is Dynavax Technologies (DVAX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (DVAX) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Moving Average Crossover Alert: Dynavax Technologies

by Zacks Equity Research

Dynavax Technologies Corporation (DVAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Equity Research

Dynavax's Partner Doses First Patient in Coronavirus Study

by Zacks Equity Research

Dynavax's (DVAX) China-based partner initiates dosing in a phase I study evaluating a COVID-19 vaccine using the company's proprietary CpG 1018 adjuvant. Preliminary data are expected in August.

Zacks Equity Research

Glaxo's Partner Begins Phase I Study on Coronavirus Vaccine

by Zacks Equity Research

Glaxo (GSK) has several collaborations to make its pandemic adjuvant technology available to partners who are making adjuvanted COVID-19 vaccine candidates.

Zacks Equity Research

Dynavax Technologies (DVAX) Jumps: Stock Rises 6.6%

by Zacks Equity Research

Dynavax Technologies (DVAX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Equity Research

Dynavax Closes Enrollment in Renal Disease Study on Heplisav-B

by Zacks Equity Research

Dynavax (DVAX) is developing its hepatitis B vaccine, Heplisav-B, in patients with end-stage renal disease undergoing hemodialysis in a phase I study.

Zacks Equity Research

Implied Volatility Surging for Dynavax Technologies (DVAX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.

Zacks Equity Research

Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More

by Zacks Equity Research

The biotech sector remains in focus with pipeline updates on coronavirus treatments.

Zacks Equity Research

Why Dynavax Technologies (DVAX) Stock Might be a Great Pick

by Zacks Equity Research

Dynavax Technologies (DVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Dynavax Technologies (DVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ritujay Ghosh headshot

Gilead Increases Enrollment Target, Pharma Rally Continues

by Ritujay Ghosh

Substantial progress has been made over the past few weeks with pharmaceutical companies speeding up development of coronavirus vaccines.

Zacks Equity Research

Dynavax Technologies (DVAX) in Focus: Stock Moves 9.1% Higher

by Zacks Equity Research

Dynavax Technologies (DVAX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Ritujay Ghosh headshot

Gilead Brings Likely Coronavirus Cure, Pharma Rallies on R&D

by Ritujay Ghosh

Shares of Gilead Science Inc. (GILD) rally on media reports that severe coronavirus patients were responding positively to the company's experimental treatment, remdesivir.

Ritujay Ghosh headshot

Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up

by Ritujay Ghosh

If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.

Sweta Jaiswal, FRM headshot

Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress

by Sweta Jaiswal, FRM

The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

Sweta Jaiswal, FRM headshot

Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development

by Sweta Jaiswal, FRM

The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

Zacks Equity Research

Dynavax Technologies (DVAX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -3.03% and -11.29%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dynavax Technologies (DVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is the Options Market Predicting a Spike in Dynavax (DVAX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Dynavax (DVAX) stock based on the movements in the options market lately.

Zacks Equity Research

Dynavax Technologies (DVAX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -22.50% and 5.07%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Dynavax Technologies (DVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.